Notice pursuant to art. 144-octied, para. 2 of CONSOB regulation No. 1971/1999

DIASORIN: NOTICE PURSUANT TO ART. 144-OCTIES, PARA. 2 OF CONSOB REGULATION N. 11971/1999 - FILING OF THE LISTS FOR THE APPOINTMENT OF THE BOARD OF DIRECTORS AND BOARD OF STATUTORY AUDITOR - REOPENING OF THE TERMS FOR THE FILING OF THE LIST FOR THE APPOINTMENT OF THE BOARD OF STATUTORY AUDITORS

Saluggia, April 4, 2025 - With reference to the Shareholders' meeting called for April 28, 2025 on a single calling, DiaSorin S.p.A. (FTSE MIB: DIA) announces that at the date of April 3, 2025 (final date for the filing of the lists), only one list of candidates for the appointment of the Board of Directors and Board of Statutory Auditors was filed by the shareholder IP Investimenti e Partecipazioni S.r.l.

Considered that at the date of April 3, 2025 only the abovementioned list for the appointment of the Board of Statutory Auditors was filed, according to art. 144-sexies, para. 5 of Consob Regulation n. 11971/1999 the minority shareholders will be entitled to file additional lists (along with the documents requested by the by-laws and the applicable law provisions) for the appointment of the Board of Statutory Auditors, until April 6, 2025. The threshold for the filing of the above lists is halved (thus equal to 0.5% of the share capital of Diasorin S.p.A.)

The lists, along with the documents requested by the by-laws and applicable law provisions, will be made available to the public no later than April 7, 2025 at the Company's registered office, on the Company' website (int.diasorin.com, section "Governance"/ "Shareholders meetings"/"2025") and on the authorized storage mechanism used by the Company available on the websitewww.emarketstorage.com.

ABOUT DIASORIN

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, Diasorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 35 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions Diasorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info atwww.diasorin.com

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

INVESTOR RELATIONS